Advertisement

PentaVision

Retinal Physician

Article

36-Week Results From QUASAR

Results showed noninferiority of the 8 mg aflibercept groups compared with the 2 mg groups with a visual acuity gain of around 17 to 18 letters.

Richard P. Gale, BSc, MBChB, FRCP, FRCOphth, MEd, PhDMichael A. Singer, MD
Retinal Physician April 24, 2025
5 Key Takeaways

  • 1

    The QUASAR study evaluated high-dose aflibercept (8 mg) versus standard dose (2 mg) in patients with retinal vein occlusion.

  • 2

    At week 36, the 8 mg groups demonstrated noninferiority with a visual acuity gain of 17 to 18 letters compared to the 2 mg groups.

  • 3

    The study included 237 sites across 27 countries, with nearly 95% of participants completing the 36-week assessment.

  • 4

    Safety results showed no new safety signals, with low rates of intraocular pressure increase and inflammation across both dosage groups.

  • 5

    The study's design allows for potential treatment interval extensions, with nearly 70% of the 8 mg group assigned to longer intervals by week 36.